Physician

Minaxi K Rathod, MD

According to 2025 Medicare claims, Minaxi Rathod, MD (NPI: 1437137981) practices infectious disease in the Sherman-Denison, TX market, with the plurality of this provider's patient population coming from Grayson, TX. This provider's primary affiliated billing organization is GRAYSON MEDICAL CONSULTANTS PA (NPI: 1861538985; TIN: 752778121) and primary practice location at 75092-7069.

Rathod's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 596 traditional Medicare patients, billed 4,305 HCPCS/CPT codes, and received $296,439 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,033 prescription claims across 256 beneficiaries totaling $1,465,254 in drug costs, led by Biktarvy (Bictegrav/Emtricit/Tenofov Ala). 2023 DME data shows 53 claims. Open Payments data shows 24 records totaling $17,426. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $818,938 to $1,465,254. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $46,451 to $8,880.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	936	7,676	$521,167
2016	933	6,738	$448,837
2017	1,042	6,839	$462,939
2018	1,106	7,187	$488,476
2019	1,049	7,627	$554,311
2020	1,223	9,302	$685,111
2021	1,025	8,194	$572,932
2022	844	6,379	$442,834
2023	657	4,825	$341,569
2024	596	4,305	$296,439

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	1,209	$818,938
2016	142	961	$721,356
2017	141	901	$918,320
2018	170	1,035	$896,424
2019	205	1,157	$772,718
2020	220	1,115	$1,026,744
2021	203	1,573	$1,520,882
2022	216	1,786	$1,612,218
2023	370	2,098	$1,807,307
2024	256	2,033	$1,465,254

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	37	131	$36,379
2016	78	148	$30,016
2017	72	121	$20,995
2018	33	63	$12,138
2019	N/R	52	$15,904
2020	N/R	13	$105
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	53	$23,549
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	239	276	$130
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	256	302	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	75	121	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	51	99	$63
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	496	3,269	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	98	2,940	$385,964
Dovato	Dolutegravir Sodium/Lamivudine	86	2,580	$249,691
Gammaplex	Immun Glob G(Igg)/Gly/Iga 0-50	39	1,092	$159,457
Cabenuva	Cabotegravir/Rilpivirine	22	1,292	$139,461
Symtuza	Darunavir/Cob/Emtri/Tenof Alaf	12	840	$121,065

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$172	ViiV Healthcare Company
Research Payments	Reported research-related payment or transfer-of-value amount.	13	$17,254	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Minaxi K. Rathod, MD?

Tedicare shows public-source Medicare data for Minaxi K. Rathod, MD (NPI 1437137981), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Minaxi K. Rathod, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Minaxi K. Rathod, MD?

Minaxi K. Rathod, MD is linked to GRAYSON MEDICAL CONSULTANTS PA (billing NPI 1861538985) in the available physician profile data.

Does Minaxi K. Rathod, MD have Open Payments data?

Minaxi K. Rathod, MD has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.